A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

Key facts

Sponsor

Eli Lilly and Company

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Eli Lilly and Company

Intervention

Abemaciclib(drug)

Enrollment

453 enrolled

Eligibility

18 years · All sexes

Timeline

2014 – 2026

Study locations (30)

• Highlands Oncology Group, Fayetteville, Arkansas, United States
• St. Bernards Medical Center, Jonesboro, Arkansas, United States
• City of Hope National Medical Center, Duarte, California, United States
• University of California - San Diego, La Jolla, California, United States
• Loma Linda University School of Medicine, Loma Linda, California, United States
• CBCC Global Research, Inc., Los Angeles, California, United States
• Central Coast Medical Oncology Corporation, Los Angeles, California, United States
• Fort Wayne Oncology & Hematology, Los Angeles, California, United States
• SMO TRIO -Translational Research, Los Angeles, California, United States
• St. Joseph Heritage Medical Group, Los Angeles, California, United States
• UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
• Cancer Care Associates Medical Group, Los Angeles, California, United States
• Dignity Health Care Institute, Sacramento, California, United States
• Alegent Immanuel Cancer Center, Englewood, Colorado, United States
• Jewish Hospital, Englewood, Colorado, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06694454
  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  National Cancer Institute (NCI)
• RECRUITINGNANCT07398599
  Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
  Second Affiliated Hospital of Nanchang University
• RECRUITINGPHASE1, PHASE2NCT07480213
  Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  Beijing Biotech
• RECRUITINGPHASE2NCT07329322
  Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
• RECRUITINGPHASE1, PHASE2NCT07227597
  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE1NCT07348211
  First in Human Study of SIM0610 in Solid Tumors
  Jiangsu Simcere Pharmaceutical Co., Ltd.
• RECRUITINGNANCT07161310
  Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
  Goethe University
• RECRUITINGPHASE2NCT07304739
  Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  Tianjin Medical University Cancer Institute and Hospital

See all trials for Small cell lung cancer →